Loading
Life sciences · Journal article
Scientific Reports · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Anal squamous cell carcinoma (ASCC) is a rare malignancy associated with high-risk HPV, with rising incidence among younger adults. While immunotherapy has improved outcomes in metastatic ASCC, treatment for localized disease remains largely unchanged, with high recurrence rates. This study provides comprehensive exome and transcriptome profiling of 40 stage I-III non-metastatic ASCC patients treated with curative chemoradiotherapy (CRT) to identify predictors of treatment response and progression-free survival. Transcriptomic analysis revealed 350 differentially expressed genes between complete responders (CR) and non-complete responders (NCR) (p-value < 0.01; FC > 2). CR was associated with modulation of immune-related pathways, cytokine production, epidermis development, cell differentiation, and signaling pathways associated with TNFA/NFkB and epithelial to mesenchymal transition. Immune infiltrate analysis showed significant enrichment of CD8 + central memory T cells ( p = 0.008) in CR cases, correlating with increased tertiary lymphoid structure and improved overall ( p = 0.0026) and disease-free survival ( p = 0.0098). Exome-seq identified alterations in cancer driver genes without association to CRT response, despite high tumor mutational burden (TMB) was significantly associated with shorter overall ( p = 0.03) and disease-free survival ( p = 0.027) compared with low TMB cases. These findings highlight the potential of incorporating gene expression signatures (e.g., FDCSP, ALDOB, ADGRB1, SPINK7 ) alongside immune-related markers into clinical practice to enhance the prediction of treatment response and guide personalized therapies in ASCC. A robust and functionally active immune microenvironment, characterized by computationally inferred immune-cell populations and the presence of tertiary lymphoid structures, emerges as a hallmark of complete response and improved survival in ASCC patients undergoing chemoradiotherapy.